Update for the MRCP, Volume 2

Update for the MRCP

Volume 2

By Andrews


CONTENTS
Questions

Basic science, immunology and genetics
1. Mechanisms of cell death
2. T cell activation
3. T helper (Th2) cells
4. Chemokines
5, 6. Chemokines and HIV-1 receptors
7. IGE in asthma
8. Allergen immunotherapy
9. Vaccination for hepatitis B virus (HBV)
10. Flow cytometry
11. The human genome project
12. Neurogenetics
13. The mitochondrial genome
14. Prothrombin-gene G20210A mutation
15. Nutritional requirements
Pharmacology and drug development
16. Drug development
17. The yellow card scheme for reporting suspected adverse reactions
18. Study designs
19. Concerning clinical trials
20. Cytochrome P450 enzymes
21. Oral bioavailability of drugs augmented by grapefruit juice
Therapeutics
22, 23. Prolongation of the QT interval
24. Inhaled beclomethasone dipropionate
25. Cyclo-oxygenase (COX)
26. Sildenafil
27. The new epilepsy drugs
28. Drug treatments for depression
29. Drug treatment of Alzheimers disease
30. 5 fluorouracil
31. Paclitaxel
32. Doxorubicin induced cardiomyopathy
33. Ecstasy
34. Cannabis
35. Carbon monoxide poisoning
36. Drug induced hypokalaemia
37. Treating a patient with glucocorticoids
Neurology
38. Haematological causes of acute stroke
39. Status epilepticus
40. Friedreichs ataxia
41. diabetic peripheral neuropathy
42. Parkinsons disease
43. Neurosurgical treatments of Parkinsons disease
44. Trinucleotide repeat disorders
45. Diagnosis and management of migraine
46. Pathology of migraine
47. Management of headache
Respiratory medicine
47. Brittle asthma
48. Bronchial asthma
50. Alpha antitrypsin (AAT)
51, 52. Pulmonary fibrosis
53. Nebuliser therapy
54. Primary pulmonary hypertension
55. Lung volume reduction surgery
56. Lung transplantation
Endocrinology
57. Causes of hirsutism in women
58. Polycystic ovary syndrome
59. Endocrine hypertension
60. Phaeochromocytoma
61. Multiple endocrine neoplasia (MEN)
62, 63. Type 2 diabetes mellitus
64. Hypothyroidism
65, 66. Common causes of primary hypothyroidism
67. Adult growth hormone deficiency (GHD)
68. Carcinoid tumours
Cardiology
69. Cardiac physiology
70. Unstable angina and non-Q wave myocardial infarction
71. Ventricular fibrillation (VF)
72, 73. Chronic heart failure
74. Ischaemic heart disease
75. Antiplatelet agents in coronary artery disease
76. Arrhythmogenic right ventricular dysplasia (ARVD)
77. Right ventricular infarction
Gastroenterology
78. Primary biliary cirrhosis
79. Acute pancreatitis
80. Barretts oesophagus
81. Management of obesity
82. Hepatitis A infection
83. Haemochromatosis
84. Assessment of nutritional status
85. Nutritional supplementation
86. Patient presenting with general malaise as a result of short bowel syndrome
87. Management of gastro-oesophageal reflux disease
88, 89 Coeliac disease

Nephrology
90. The nephrotic syndrome
91, 92. Solid organ transplantation
93. Atheromatous renovascular disease
94. During pregnancy
95. Kidney stones
96. Acute renal failure
97. End-stage renal failure
98. Management of rhabdomyolysis
99. IgA nephropathy
Infectious diseases
100 Leprosy
101. Parasite presentation
102. Pathology mediated by exotoxins
103. Nematodes that migrate through the lung
104. Diseases transmitted by specific vectors
105. Relative contraindications to the use of antimalarial drugs
106. Clinical diagnostic methods of choice
107. Infections
108. Antimicrobials
HIV
109. Clinical features of acute HIV-1 infection
110. Pathogeneisis of acute HIV-1 infection
111. Effect of HIV infection on the immune system
112. Immune reconstitution in HIV positive patients treated with highly active antiretroviral therapy
(HAART)
113. British HIV association (BHIVA) guidelines for the treatment of HIV-1 infection
114. Treatment of HIV infected patients with highly active antiretroviral therapy (HAART)
115. Reservoirs of HIV-1 in patients receiving highly active antiretroviral therapy (HAART)
116. Adverse effects of antiretroviral therapy
117. Resistance to antiretroviral drugs
Oncology
118, 119. Radiotherapy
120. Adjuvant chemotherapy
121. Immunotherapy
122. Tamoxifen
123. Screening
124 Non small cell lung cancer
125. High grade B cell non Hodgkins lymphoma
126. Control of cancer pain
Haematology
127. Patients with multiple myeloma
128. Patients with sickle cell disease
129. Heparin-induced thrombocytopenia (type 2)
130. High homocysteine levels
131. Chronic myeloid leukaemia (CML)
132. Essential thrombocytopenia
133. Severe haemophilia A
134. Human T-cell leukaemia (HTLV) viruses
135. Acute myeloid leukaemia (AML)
Rheumatology
136. Anti-neutrophil cytoplasmic antibodies (ANCA)
137. Scleroderma
138. HIV infection compared to the normal population
139. Mixed cryoglobulinaemia
140. Poor prognostic markers in patients presenting with rheumatoid arthritis
141. Bone mineral density (BMD)
Dermatology
142. Acne vulgaris
143. Alopecia
144. Atopic eczema
145. Pyoderma gangrenosum
146. Mycosis fungoides
147. Psoriasis
148. Effects of ultraviolet radiation (UVR) on the skin
149. Skin cancer in organ-transplant recipients
150. Neurocutaneous disorders

Answers

VIVA questions

References

Abbreviations

Index